LONDON, April 21, 2014 /PRNewswire/ --
The trading session on Thursday, April 17, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,408.54, down 0.10% and the NASDAQ Composite closed at 4,095.52, up 0.23%. The S&P 500 finished the session 0.14% higher at 1,864.85. During the trading session, seven out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day flat at 658.58, while it has edged lower by 0.30% in previous three months. Investor-Edge has initiated coverage on the following equities: TherapeuticsMD Inc. (NYSE MKT: TXMD), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), GW Pharmaceuticals PLC (NASDAQ: GWPH) and Depomed Inc. (NASDAQ: DEPO). Free technical research on TXMD, PCRX, GWPH and DEPO can be downloaded upon signing up at:
TherapeuticsMD Inc.'s stock finished the Thursday's session 4.48% higher at $4.90. A total of 1.20 million shares were traded, which was below its three months average volume of 1.35 million shares. The stock moved between $4.58 and $5.00 during the trading session. TherapeuticsMD Inc.'s shares have advanced 3.38% in the previous three trading sessions, while the same has lost 32.51% in the last one month and 5.95% since the beginning of this year. The company's stock is trading below its 50-day moving average. The stock's 50-day moving average of $6.34 is greater than its 200-day moving average of $4.42. Further, TherapeuticsMD Inc.'s stock has a Relative Strength Index of 35.29. Sign up today to read free research on TXMD at:
Shares in Pacira Pharmaceuticals Inc. fluctuated between $65.28 and $68.90 before ending the day 2.47% lower at $66.05. Pacira Pharmaceuticals Inc.'s stock reported a trading volume of 0.19 million shares on Thursday, which was below its three months average volume of 0.50 million shares. Pacira Pharmaceuticals Inc.'s shares have advanced 3.32% in the previous three trading sessions and 14.89% on YTD basis, while the company's stock has declined 10.76% in the last one month. The stock is trading below its 50-day moving average. Pacira Pharmaceuticals Inc.'s 50-day moving average of 70.07 is above its 200-day moving average of $53.29. Moreover, the company's stock has an RSI of 47.06. Sign up today to read free research on PCRX at:
On Thursday, GW Pharmaceuticals PLC's stock gained 3.49%, closing the day at $46.20. The stock recorded a trading volume of 0.30 million shares, which was below its three months average volume of 0.41 million shares. The stock oscillated between $43.50 and $47.59 during the trading session. GW Pharmaceuticals PLC's shares have gained 1.36% in the previous three trading sessions and 11.22% since the start of this year. However, the company's shares have lost 32.57% in the last one month. The stock is trading below its 50-day moving average of $62.38, while the stock's 50-day moving average is above its 200-day moving average of $35.19. Additionally, shares of the company have an RSI of 33.20. Sign up today to read free research on GWPH at:
Shares in Depomed Inc. recorded a trading volume of 0.60 million shares, which was below its three months average volume of 1.11 million shares. On Thursday, the stock ended the day at $12.87, up 0.31%, and registered an intraday range of $12.56 and $13.18. Shares of the company traded at a PE ratio of 17.37. Depomed Inc.'s shares have fallen by 1.15% in the previous three trading sessions and 14.94% in the last one month, while the same has gained 21.64% on YTD basis. The company's stock is trading below its 50-day moving average. Depomed Inc.'s 50-day moving average of $13.42 is above its 200-day moving average of $9.47. Furthermore, the shares of the company have an RSI of 43.98. Sign up today to read free research on DEPO at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.